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INTRODUCTION 
Rifaximin (Fig 1) (RFX) is a newer antibiotic, used for the 
treatment of patients (more than 12 years of age) with 
traveller’s diarrhoea caused by non-invasive strains of 
Escherichia coli1. Rifaximin2 is benzimdazole derivative 
and chemically it is a 
2S,16Z,18E,20S,21S,22R,23R,24R,25S, 26S, 27S, 28E-
5,6,21,23,25-pentahydroxy- 27-methoxy-2,4,11, 16, 20,22, 
24, 26, - octamethyl-2,.7-epoxypentadeca- [1,11,13] 
trienimino) benzofuro [4,5-e] pyrido [1,2-a]- 
benzimidazole-1,15(2H)- dione, 25-acetate. It is a 
structural analog of Rifampin. RFX is a product of 
synthesis of Rifamycin, an antibiotic with low 
gastrointestinal absorption and good antibacterial activity3. 
Rifaximin binds to the beta-subunit of bacterial DNA-
dependent RNA polymerase and prevents catalysis of 
polymerization of deoxyribonucleotides into a DNA 
strand. As a result, bacterial RNA synthesis is inhibited. In 
vitro studies of RFX have demonstrated broad-spectrum 
coverage including Gram-positive, Gram-negative, and 
anaerobic bacteria as well as a limited risk of bacterial 
resistance4. Furthermore, RFX does not bind to RNA 
polymerase in eukaryotic cells, thus human cell production 
is not affected. Compared with other antibiotics, RFX has 
a lower rate of fecal pathogenic eradication, so depletion 
of normal gastrointestinal flora is reduced5. Methods 
reported for the determination of RFX in pharmaceutical 
dosage forms and biological fluids include RPHPLC
6-8
, 
LC-MS9-12 and spectrophotometric13-14 methods have been 
developed for the determination of RFX in pharmaceutical 
formulations and biological fluids. Impurity profiles of 
Rifaximin were also studied by using Diagnostic fragment-
ion-based extension strategy (DFIBES) and derivative 
resolution of UV spectra 15-16. In the present work we 
developed simple, rapid, precise and accurate robust liquid 
chromatographic method for the determination of RFX 
tablets. Previous reported methods have from one or other 
disadvantages and therefore the authors have developed a 
novel stability indicating liquid chromatographic method 
which was validated as per ICH guidelines17. 
 
Figure 1: Chemical structure of Rifaximin (RFX) 
EXPERIMENTAL 
Chemicals and solutions 
Rifaximin standard (purity ≥ 99.0 %) was obtained from 
Torrent Pharmaceuticals Limited, India). Methanol (HPLC 
grade), Tetra butyl ammonium hydrogen sulphate 
(Spectrochem Pvt. Ltd.)  Sodium hydroxide (NaOH) and 
hydrochloric acid (HCl) and Hydrogen peroxide (H2O2) 
were obtained from Merck (India). Rifaximin is available 
(Label claim: 200 mg) with brand names RCIFAX (Lupin, 
India) and TORFIX (Torrent Pharmaceuticals, India). All 
chemicals were of analytical grade and used as received. 
HPLC instrumentation and conditions 
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Chromatographic separation was achieved by using a 
Lichrocart / Lichrosphere 100 C-18 (250 mm × 4.6 mm 
i.d., 5 μm particle size) column of Shimadzu Model LC-
Class-Vp version 6.12 SPI, equipped with UV-VIS 
detector Model SPD-10A maintained at 25 ºC. Isocratic 
elution was performed using 10 mM TBAHS and 
methanol (90:10, v/v). The overall run time was 5 min. and 
the flow rate was 1.0 mL/min. 20 μl of sample was 
injected into the HPLC system.  
The mobile phase was prepared by accurately weighed and 
transferred 3.3954 grams of tetra butyl ammonium 
hydrogen sulphate (10mM TBAHS) (pH 3.37) in to a 1000 
mL volumetric flask, dissolve and diluted to volume with 
HPLC grade water.  
Rifaximin stock solution (1000 μg/mL) was prepared by 
accurately weighing 25 mg of Rifaximin in a 25 mL amber 
volumetric flask and making up to volume with mobile 
phase. Working solutions for HPLC injections were 
prepared on a daily basis from the stock solution in a 
solvent mixture of TBAHS and methanol (10:90 v/v) 
(mobile phase). Solutions were filtered through a 0.45 μm 
membrane filter prior to injection. 
Analysis of marketed formulation (Tablets) 
Twenty tablets from each brand of marketed formulations 
(RCIFAX and TORFIX) were procured from the medical 
store, weighed and crushed to a fine powder. Powder 
equivalent to 25 mg Rifaximin was accurately weighed 
and dissolved in mobile phase in a 25 ml volumetric flask. 
The volumetric flask was sonicated for 30 min and filtered 
through 0.45 μm nylon filter before injection. The filtrate 
obtained from the extracted marketed formulations 
(RCIFAX and TORFIX) was diluted as per the 
requirement and 20 μL was injected in to the HPLC system 
for conducting the assay.  
Forced Degradation Studies/Specificity 
The study was intended to ensure the effective separation 
of RFX and its degradation peaks of formulation 
ingredients at the retention time of RFX. Separate portions 
of drug product and ingredients were exposed to the 
following stress conditions to induce degradation. Forced 
degradation studies were performed to evaluate the 
stability indicating properties and specificity of the 
method18. All solutions for use in stress studies were 
prepared at an initial concentration of 1 mg/mL of RFX 
and refluxed for 30 min at 60 ºC. All samples were then 
diluted in mobile phase to give a final concentration of 20 
μg/mL and filtered before injection. 
Acid and alkali degradation studies 
Acid decomposition was carried out in 0.1 M HCl at a 
concentration of 20 μg/mL RFX and after refluxation for 
30 min at 60 ºC in thermostat the stressed sample was 
cooled, neutralized and diluted with mobile phase. 
Similarly stress studies in alkaline conditions were 
conducted using a concentration of 20 μg/mL in 0.1 M 
NaOH and refluxed for 30 min at 60 ºC in thermostat. 
After cooling the solution was neutralized and diluted with 
mobile phase. 
 Oxidation 
Solutions for oxidative stress studies were prepared using 
3% H2O2 at a concentration of 20 μg/mL of RFX and after 
refluxation for 30 min at 60 ºC on the thermostat the 
sample solution was cooled and diluted accordingly with 
the mobile phase. 
Thermal Degradation Study 
For thermal stress testing, the drug solution (20 μg/mL) 
was heated in thermostat at 80 ºC for 30 min, cooled and 
used. 
Photo stability 
The drug solution (20 μg/mL) for photo stability testing 
was exposed to UV light for 4 hour UV light (365 nm) 
chamber and analyzed. 
Method validation 
The method was validated for the following parameters: 
system suitability, linearity, limit of quantitation (LOQ), 
limit of detection (LOD), precision, accuracy, selectivity 
and robustness. 
Linearity 
Linearity test solutions for the assay method were prepared 
from a stock solution at different concentration levels of 
the assay analyte concentration (1, 2, 5, 10, 20, 50, 100, 
120, 150, 180 and 200 μg/mL). 20 μL of each solution was 
injected in to the HPLC system and the peak area of the 
chromatogram obtained was noted. The solutions extracted 
from the marketed formulations were injected in to the 
HPLC system and the peak area of the chromatograms was 
noted. The analytical curve was evaluated on three 
different days. The peak area vs. concentration data was 
analyzed with least squares linear regression. The slope 
and y-intercept of the calibration curve was reported. 
Precision 
The intra-day precision of the assay method was evaluated 
by carrying out 9 independent assays of a test sample of 
RFX at three concentration levels (10, 20 and 50 μg/mL) 
(n=3) against a qualified reference standard. The %RSD of 
three obtained assay values at three different concentration 
levels was calculated. The inter-day precision study was 
performed on three different days i.e. day 1, day 2 and day 
3 at three different concentration levels (10, 20 and 50 
μg/mL) and each value is the average of three 
determinations (n=3). The % RSD of three obtained assay 
values on three different days was calculated. 
Accuracy 
The accuracy of the assay method was evaluated in 
triplicate at three concentration levels (80, 100 and 120%), 
and the percentage recoveries were calculated. Standard 
addition and recovery experiments were conducted to 
determine the accuracy of the method for the 
quantification of RFX in the drug product. The study was 
carried out in triplicate at 18, 20 and 22 μg/mL. The 
percentage recovery in each case was calculated. 
Robustness 
The robustness of the assay method was established by 
introducing small changes in the HPLC conditions which 
included wavelength (452 and 456 nm), percentage of 
methanol in the mobile phase (88 and 92%) and flow rate 
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(0.9 and 1.1 mL/min). Robustness of the method was 
studied using six replicates at a concentration level of 20 
μg/mL of RFX.  
Sensitivity/Limit of quantification (LOQ) and limit of 
detection (LOD)  
The limit of quantification (LOQ) and limit of detection 
(LOD) were based on the standard deviation of the 
response and the slope of the constructed calibration curve 
(n=3), as described in International Conference on 
Harmonization guidelines Q2 (R1)16. Sensitivity of the 
method was established with respect to limit of detection 
(LOD) and LOQ for RFX. LOD and LOQ were 
established by slope method as mentioned below. 
                   3.3 × standard deviation of y-intercept 
LOD =     -------------------------------------------------- 
                         Slope of the calibration curve 
 
                        10 × standard deviation of y-intercept 
LOQ=       -------------------------------------------- 
                        Slope of the calibration curve 
 
LOD and LOQ were experimentally verified by injecting 
six replicate injections of each impurity at the 
concentration obtained from the above formula. 
Solution stability and mobile phase stability 
The solution stability of RFX in the assay method was 
carried out by leaving both the sample and reference 
standard solutions in tightly capped volumetric flasks at 
room temperature for 48 h. The same sample solutions 
were assayed at 12 h intervals over the study period. The 
mobile phase stability was also assessed by assaying the 
freshly prepared sample solutions against freshly prepared 
reference standard solutions at 12 h intervals up to 48 h. 
The prepared mobile phase remained constant during the 
study period. The % RSD of the RFX assay was calculated 
for the mobile phase and solution stability experiments. An 
additional study was carried out using the stock solution by 
storing it in a tightly capped volumetric flask at 4 ºC. 
RESULTS AND DISCUSSION 
The present proposed method is more simple, precise and 
accurate in comparison to the reported methods in the 
literature (Table 1). No stability indicating liquid 
chromatographic method was reported earlier. The 
linearity range for the methods reported in the literature 
was narrow and some of the methods are applicable only 
for bio analytical determination of Rifaximin. The present 
developed method is more sensitive and can be used in a 
wide concentration range for the determination of 
Rifaximin in pharmaceutical formulations. Satisfactory 
resolution was achieved with use of a mixture of TBAHS 
and methanol (10:90 v/v) (Fig. 2A) and C18 column was 
adopted for the analysis as it has provided a better 
separation of the analytes. UV detection was carried out at 
454 nm. The present stability-indicating method for the 
determination of RFX in pharmaceutical formulations is 
specific because the drug peak was well separated even in 
the presence of degradation products. Overall, the data 
demonstrated that the excipients and the degradation 
products did not interfere with the RFX peak, indicating 
the selectivity of the method. The complete separation of 
the analytes was accomplished in less than 5 min and the 
method can be successfully applicable to perform long-
term and accelerate stability studies of RFX formulations.
 
Table 1: Comparison of the performance characteristics of the present HPLC method with the published methods 
S.No Method /Reagent (nm) Linearity Remarks Ref 
1. (HPLC) 
Methanol : phosphate buffer 
(70:30, v/v) 
293 5-30 Very narrow linearity 
range 
6 
2. (HPLC) 
Acetonitrile : Ammonium acetate (85:15, v/v) 
 
- 
5-50 Very narrow linearity 
range 
7 
3. (HPLC) 
Acetonitrile : water : Acetic acid (18:82:0.1, v/v) 
- 0.1-20 Rat serum and urine 8 
4. (LC-ESI/MS/MS) 
Acetonitrile : Acetic acid 
(Gradient mode) 
- (0.5-10)10
-3
 Rat serum 9 
5. (LC-MS) 
Ammonium acetate : Methanol (pH-4.32) 
- (0.5-10)10
-3
 Human Plasma 10 
6. (LC-MS) 
Ammonium formate : Acetonitrile (20:80, v/v) 
- (0.2-200)10
-4
 Human Plasma 11 
7. (LC-ESI/MS) - (0.1-10)10
-4
 Dried blood spots 12 
8. (Spectrophotometry) 
Fecl3+MBTH(Method A) 
Alkaline borate buffer     (pH 12) (Method B) 
637 
 
296 
5-25 
 
5-25 
Very narrow linearity 
range 
13 
9. (Spectrophotometry) 
Water (Method A) 
Methanol (Method B) 
437 
 
474 
1-200 
 
2-100 
Colorimetric method 14 
10. (HPLC) 
TBAHS : Methanol      (10:90, v/v) 
 
454 
 
1-200 
Wide linearity range, 
stability indicating 
method 
Present 
Work 
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HPLC method development and optimization 
Initially the stressed samples were analyzed using a 
mobile phase consisting of TBAHS: Acetonitrile (45:55, 
v/v) at a flow rate of 1.0 mL/min. Under these conditions, 
the resolution and peak symmetry were not satisfactory 
and two peaks were observed, so the mobile phase was 
changed to TBAHS: methanol (45:55 v/v) with a flow 
rate of 1.0 mL/min in which tailing was observed and the 
retention time of the drug peak was more than 10 mins. 
Therefore mobile phase containing TBAHS: methanol 
(90:10, v/v) was chosen as the best chromatographic 
response for the entire study where the drug peak was 
well resolved with good symmetry and sharpness. 
Method validation 
 System suitability 
The system suitability test was performed to ensure that 
the complete testing system was suitable for the intended 
application. The parameters measured were peak area, 
retention time, tailing factor, capacity factor and 
theoretical plates. In all measurements the peak area 
varied less than 2.0%, the average retention time was 
3.625 minutes. The capacity factor was more than 2, 
theoretical plates were 7786 (more than 2000) and tailing 
factor was 1.21 (less than 2) for the RFX peak. The LOQ 
was found to be 0.786 μg/mL and the LOD was found to 
be 0.238 μg/mL. 
 Linearity 
The typical chromatogram for RFX obtained from the 
standard solution and extracted marketed formulation was 
shown in Fig. 2A & 2B. The calibration curve for RFX 
was linear over the concentration range of 1.0–200 
μg/mL. The data for the peak area of the drug in 
corresponds to the concentration was treated by linear 
regression analysis (Table 2) and the regression equation 
for the calibration curve (Fig. 3) was found to be y = 
15407x +6677 with correlation coefficient of 0.9999 
which is nearly equals to unity. 
 
 
[A] 
 
[B] 
Figure 2: Representative chromatograms of Rifaximin (20 μg/mL) [A], RCIFAX ®® (200 mg) [B] 
Table 2: Linearity of Rifaximin 
Conc.(µg/ml) *Mean area ± SD *RSD(%) 
1 15924 ± 46.18 0.29 
2 31985 ± 115.15 0.36 
5 82579 ± 255.99 0.31 
10 155168 ± 356.89 0.23 
20 301638 ±1417.69 0.47 
50 802375 ± 2808.31 0.35 
100 1557275 ± 4204.64 0.27 
120 1878632 ± 6011.62 0.32 
150 2300850 ± 17026.29 0.74 
180 2788630 ± 20078.14 0.72 
200 3069481 ± 24862.79 0.81 
*Mean of three replicates 
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Figure 3: Calibration curve of Rifaximin 
Precision 
The precision of the method was determined by 
repeatability (intra-day precision) and intermediate 
precision (inter-day precision) of the RFX standard 
solutions. Repeatability was calculated by assaying three 
samples of each at three different concentration levels (10, 
20 and 50 μg/mL) on the same day. The inter-day 
precision was calculated by assaying three samples of each 
at three different concentration levels (10, 20 and 50 
μg/mL) on three different days. The % RSD range was 
obtained as 0.28-0.55 and 0.68- 0.81 for intra-day and 
inter-day precision studies respectively (Table 3). 
 
Table 3: Intra-day and inter-day precision studies of Rifaximin 
Sample No. Conc. (µg/ml) Intra-day precision Inter-day precision 
Mean ± SD %RSD Mean ± SD %RSD 
1. 10 154143 ± 423.2004 0.28 156349 ± 1063.1732 0.68 
2. 20 311654 ± 1277.7814 0.41 310347 ± 2296.5678 0.74 
3. 50 803462 ± 4419.041 0.55 798976 ± 6471.7056 0.81 
*Mean of three replicates 
Because the stability of standard solutions can also affect 
the robustness of analytical methods, the stability of 
standard solutions of the drug substance used in this 
method was tested over a long period of time. One portion 
of a standard solution was kept at room temperature and 
the other portion was stored under refrigeration at 
approximately 4ºC and the content of these solutions was 
regularly compared with that of freshly prepared solutions. 
No change in drug concentrations were observed for 
solutions stored under refrigeration. But it is recommended 
that the sample and standard solutions must therefore, be 
freshly prepared in amber colour flasks to protect from 
light. 
Accuracy 
The method accuracy was proven by the recovery test. A 
known amount of RFX standard (10 μg/mL) was added to 
aliquots of samples solutions and then diluted to yield total 
concentrations as 18, 20 and 22 μg/mL as described in 
Table 4. The assay was repeated over 3 consecutive days. 
The resultant % RSD was in the range 0.15-0.36 (<2.0 %) 
with a recovery 98.70-99.71 %. 
Table 4: Accuracy-recovery study of Rifaximin by standard-addition method 
Sample No Spiked  
Concentration(µg/ml) 
*Measured  
 Concentration(µg/ml) 
Recovery* (%) %RSD 
1. 16(80%) 15.91 99.44 0.15 
2. 20(100%) 19.74 98.70 0.23 
3. 24(120%) 23.93 99.71 0.36 
*Mean of three replicates 
Robustness 
The robustness of an analytical procedure refers to its 
ability to remain unaffected by small and deliberate 
variations in method parameters and provides an indication 
of its reliability for routine analysis [16]. The robustness of 
the method was evaluated by assaying the same sample 
under different analytical conditions deliberately changing 
from the original condition. The detection wavelength was 
set at 452 and 456 nm (± 2 nm), the ratio of percentage of 
TBAHS: Methanol in the mobile phase was applied as 
8:92 and 12:88 (± 2 %, v/v), the flow rate was set at 0.9 
and 1.1 mL/min (± 0.1 mL/min). The results obtained 
(Table 5) from assay of the test solutions were not affected 
by varying the conditions and were in accordance with the 
results for original conditions. The % RSD value of assay 
determined for the same sample under original conditions 
and robustness conditions was less than 2.0% (0.35-0.78) 
indicating that the developed method was robust.
y = 15407x + 6677.
R² = 0.999
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Table 5: Robustness study of Rifaximin 
Parameter Condition *Mean peak area Statistical analysis 
*Mean ± SD (%RSD) 
Flow rate 0.9 306828 309074 ± 1976.69 (0.64) 
1.0 309845 
1.1 310549 
Detection wave length(nm) 452 307855 308613 ± 1076.35 (0.35) 
454 309845 
456 308139 
Mobile phase composition 
(TBAHS:Methanol,v/v) 
8:92 314243 312640.67 ± 2429.74 (0.78) 
10:90 309845 
12:88 313834 
*Mean of three replicates 
Selectivity/specificity 
The specificity of the developed method was determined 
by injecting sample solutions (20μg/mL) which were 
prepared by forcibly degrading under such stress 
conditions as heat, light, oxidative agent, acid and base 
under the proposed chromatographic conditions. The 
stability indicating capability of the method was 
established from the separation of RFX peak from the 
degraded samples. The degradation of RFX was found to 
be very similar for both the tablets and standard. Typical 
chromatograms obtained following the assay of stressed 
samples are shown in Fig. 4 A-E. 
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[D] 
 
[E] 
Figure 4: Representative chromatograms of Rifaximin (20 μg/mL) on acidic [A], alkaline [B], oxidative [C], thermal [D] 
and photolytic [E] degradations 
Solution stability and mobile phase stability 
The %RSD of the assay of RFX from the solution stability 
and mobile phase stability experiments was within 2%. 
The results of the solution and mobile phase stability 
experiments confirm that the sample solutions and mobile 
phase used during the assays were stable up to 48 h at 
room temperature and up to 3 months at 4ºC. 
 Analysis of commercial formulations (Tablets) 
The proposed method was applied for the determination of 
RFX in tablets (RCIFAX and TORFIX) and the results 
show 97.70- 98.76 % recovery (Table 6) indicates that the 
method is selective for the assay of RFX without 
interference from the excipients used in these tablets.
 
Table 6: Analysis of Rifaximin commercial formulation (Tablets) 
Sample No. Formulation Labelled claim (mg) *Amount found (mg) *Recovery (%) 
1. RCIFAX 200 198.40 99.20 
2. TORFIX 200 199.51 99.76 
*Mean of three replicates 
Forced degradation studies 
RFX standard and tablet powder were found to be quite 
stable under oxidation, alkaline and thermal degradation 
conditions. A slight decomposition was seen on exposure 
of RFX drug solution to acidic and photolytic 
degradations. During the acidic degradation, 6.63 % of the 
drug was decomposed. The benzimidazole group present 
in the RFX chemical structure may be responsible for the 
reported acidic degradation. The drug has undergone 
oxidative degradation (0.64 %) very slightly and alkaline 
(1.83 %) degradation slightly in comparison to other 
degradations (Table 7). 
 
Table 7: Forced degradation studies of Rifaximin 
Stress conditions *Mean Peak area *Drug recovered (%) *Drug decomposed (%) 
Standard Drug 304750 100 - 
Acidic Hydrolysis 254070 83.37 6.63 
Alkaline Hydrolysis 299165 98.17 1.83 
Oxidative Degradation 302786 99.36 0.64 
Thermal Degradation 289087 94.86 5.14 
Photolytic Degradation 263373 86.42 13.58 
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CONCLUSION 
The proposed stability-indicating HPLC method was 
validated as per ICH guidelines and applied for the 
determination of RFX in pharmaceutical dosage forms. 
The chromatographic elution step is undertaken in a short 
time (< 4 min). The method was found to be accurate, 
precise, robust and specific as the drug peak elution did 
not interfere with any degradants during the forced 
degradation studies and therefore the drug is more 
resistant and at the same time the proposed method can be 
successfully applied to perform long-term and accelerated 
stability studies of Rifaximin formulations and biological 
fluids. 
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